Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Making sense of non-randomized comparative treatment studies in times of Covid-19: A case study of tocilizumab

View ORCID ProfileRuth Owen, View ORCID ProfileNawab Qizilbash, Sara Velázquez Díaz, José María Castellano Vázquez, View ORCID ProfileStuart Pocock
doi: https://doi.org/10.1101/2021.04.06.21254612
Ruth Owen
1London School of Hygiene and Tropical Medicine, London, UK
2Oxon Epidemiology, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ruth Owen
Nawab Qizilbash
1London School of Hygiene and Tropical Medicine, London, UK
2Oxon Epidemiology, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nawab Qizilbash
  • For correspondence: n.qizilbash@oxonepi.com
Sara Velázquez Díaz
3Fundación de Investigación HM Hospitales, Grupo HM Hospitales, Madrid, Spain
4Facultad de Medicina, Universidad CEU San Pablo, Madrid Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José María Castellano Vázquez
3Fundación de Investigación HM Hospitales, Grupo HM Hospitales, Madrid, Spain
4Facultad de Medicina, Universidad CEU San Pablo, Madrid Spain
5Centro Nacional de Investigaciones Cardiovasculares (CNIC), Instituto de Salud Carlos III, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart Pocock
1London School of Hygiene and Tropical Medicine, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stuart Pocock
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

BACKGROUND Tocilizumab (TCZ) is an interleukin-6 inhibitor and the second established effective drug for the treatment of hospitalized patients with Covid-19. In this study, we sought to validate the recent positive findings from the randomised clinical trial RECOVERY and to evaluate the challenges in the analysis and interpretation of non-randomized comparative effectiveness studies in Covid-19.

METHODS We performed a retrospective cohort study using an openly available database of hospitalised Covid-19 patients in Spain. The primary outcome was all-cause in-hospital mortality at 28 days. We used multivariable Fine and Gray competing risk models which adjusted for both fixed and time-variant confounders to investigate the effect of TCZ on the primary outcome.

RESULTS We analysed 2547 patients hospitalised with Covid-19 between 1st January and 28th June 2020. Patients in the TCZ group tended to have more severe Covid-19 at admission, as measured by biomarkers of disease severity including CRP, D-dimer and LDH. At 28 days, 91 out of 440 TCZ patients had died compared to 267 out of 2107 patients in the control group. In multivariable analysis, there was no evidence of an association between TCZ and the primary outcome (adjusted hazard ratio 1.20, 95% CI 0.86 to 1.64, P=0.26).

CONCLUSIONS Our observational study failed to find a benefit of TCZ on all-cause in-hospital mortality in Covid-19 patients compared with randomized trials, highlighting the impact that unmeasured confounding and other sources of bias can have in a retrospective observational setting. For future observational studies, we recommend prospective data collection to ensure all variables have the necessary quality, completeness and timing for reliable treatment evaluation.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding was received for the work presented

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the ethics committee of HM Hospitales (approval number 20.05.1627-GHM).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Covid Data Saves Lives is an anonymous dataset made freely available to the international medical and scientific community by HM Hospitales

https://www.hmhospitales.com/coronavirus/covid-data-save-lives/english-version

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted April 07, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Making sense of non-randomized comparative treatment studies in times of Covid-19: A case study of tocilizumab
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Making sense of non-randomized comparative treatment studies in times of Covid-19: A case study of tocilizumab
Ruth Owen, Nawab Qizilbash, Sara Velázquez Díaz, José María Castellano Vázquez, Stuart Pocock
medRxiv 2021.04.06.21254612; doi: https://doi.org/10.1101/2021.04.06.21254612
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Making sense of non-randomized comparative treatment studies in times of Covid-19: A case study of tocilizumab
Ruth Owen, Nawab Qizilbash, Sara Velázquez Díaz, José María Castellano Vázquez, Stuart Pocock
medRxiv 2021.04.06.21254612; doi: https://doi.org/10.1101/2021.04.06.21254612

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (195)
  • Anesthesia (54)
  • Cardiovascular Medicine (489)
  • Dentistry and Oral Medicine (89)
  • Dermatology (56)
  • Emergency Medicine (168)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (211)
  • Epidemiology (5674)
  • Forensic Medicine (3)
  • Gastroenterology (215)
  • Genetic and Genomic Medicine (863)
  • Geriatric Medicine (88)
  • Health Economics (230)
  • Health Informatics (761)
  • Health Policy (390)
  • Health Systems and Quality Improvement (250)
  • Hematology (105)
  • HIV/AIDS (182)
  • Infectious Diseases (except HIV/AIDS) (6467)
  • Intensive Care and Critical Care Medicine (390)
  • Medical Education (117)
  • Medical Ethics (28)
  • Nephrology (90)
  • Neurology (846)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (162)
  • Occupational and Environmental Health (258)
  • Oncology (514)
  • Ophthalmology (163)
  • Orthopedics (44)
  • Otolaryngology (105)
  • Pain Medicine (48)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (250)
  • Pharmacology and Therapeutics (146)
  • Primary Care Research (113)
  • Psychiatry and Clinical Psychology (963)
  • Public and Global Health (2224)
  • Radiology and Imaging (376)
  • Rehabilitation Medicine and Physical Therapy (174)
  • Respiratory Medicine (312)
  • Rheumatology (109)
  • Sexual and Reproductive Health (80)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)